Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919276 | 0.86 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL4915340 | 0.82 | MCHR1 (0.55) | MCHR1KCNH2CHRM2CHRM1CHRM4 | |
| SCHEMBL27690410 | 0.81 | MCHR1 (0.59) | MCHR1KCNH2CHRM2CHRM1CHRM4 | |
| SCHEMBL1733915 | 0.81 | KDM4E (0.61) | — | |
| SCHEMBL4926337 | 0.80 | MCHR1 (0.59) | MCHR1KCNH2 | |
| Hydrochloric Acid SCHEMBL4923589 | 0.80 | MCHR1 (0.58) | MCHR1KCNH2CHRM2CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL4922916 | 0.80 | MCHR1 (0.58) | MCHR1KCNH2CHRM2CHRM1CHRM4 | |
| SCHEMBL4926474 | 0.79 | MCHR1 (0.61) | MCHR1KCNH2 | |
| Acetic Acid SCHEMBL4927369 | 0.77 | MCHR1 (0.63) | MCHR1KCNH2CHRM4 | |
| SCHEMBL4925505 | 0.77 | MCHR1 (0.62) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 1440/4885CHRM2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.